Stephen Brady, Tempest Therapeutics CEO

Tem­pest eyes piv­otal tri­al for liv­er can­cer drug af­ter un­veil­ing ear­ly PFS, OS da­ta

Months af­ter ini­tial da­ta sug­gest­ed Tem­pest Ther­a­peu­tics’ drug, when giv­en on top of Roche’s Avastin and Tecen­triq, can help shrink liv­er can­cer, the com­pa­ny is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.